Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 59 | 2023 | 2417 | 4.810 |
Why?
|
Hepatitis C, Chronic | 33 | 2022 | 1032 | 3.990 |
Why?
|
Antiviral Agents | 40 | 2022 | 3068 | 3.610 |
Why?
|
End Stage Liver Disease | 16 | 2024 | 369 | 3.570 |
Why?
|
Hepacivirus | 32 | 2022 | 1343 | 3.210 |
Why?
|
Liver Cirrhosis | 47 | 2024 | 1961 | 3.090 |
Why?
|
Hepatitis C | 26 | 2022 | 1596 | 2.820 |
Why?
|
Esophageal and Gastric Varices | 9 | 2023 | 215 | 1.830 |
Why?
|
Ribavirin | 16 | 2019 | 396 | 1.810 |
Why?
|
Hepatorenal Syndrome | 5 | 2023 | 76 | 1.550 |
Why?
|
Carbamates | 7 | 2018 | 191 | 1.540 |
Why?
|
Fluorenes | 7 | 2019 | 160 | 1.000 |
Why?
|
Benzimidazoles | 9 | 2020 | 862 | 0.980 |
Why?
|
Genotype | 18 | 2021 | 13028 | 0.930 |
Why?
|
Gastrointestinal Hemorrhage | 8 | 2023 | 1127 | 0.930 |
Why?
|
Vasoconstrictor Agents | 5 | 2023 | 653 | 0.900 |
Why?
|
Liver Failure | 5 | 2014 | 252 | 0.890 |
Why?
|
Elasticity Imaging Techniques | 8 | 2024 | 397 | 0.870 |
Why?
|
Liver Neoplasms | 16 | 2024 | 4352 | 0.860 |
Why?
|
Hepatitis B | 7 | 2022 | 709 | 0.830 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2024 | 2327 | 0.830 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2023 | 95 | 0.830 |
Why?
|
Uridine Monophosphate | 6 | 2019 | 67 | 0.810 |
Why?
|
Liver Diseases | 7 | 2024 | 1304 | 0.750 |
Why?
|
Waiting Lists | 11 | 2022 | 779 | 0.750 |
Why?
|
Sclerotherapy | 1 | 2019 | 184 | 0.600 |
Why?
|
Tissue Adhesives | 1 | 2019 | 177 | 0.580 |
Why?
|
Liver Diseases, Alcoholic | 2 | 2023 | 157 | 0.560 |
Why?
|
Drug Interactions | 2 | 2021 | 1419 | 0.560 |
Why?
|
Quinoxalines | 6 | 2020 | 296 | 0.510 |
Why?
|
Postoperative Care | 3 | 2017 | 1475 | 0.510 |
Why?
|
Alcoholism | 3 | 2023 | 1979 | 0.510 |
Why?
|
Liver | 17 | 2024 | 7559 | 0.500 |
Why?
|
Tissue Donors | 9 | 2022 | 2392 | 0.490 |
Why?
|
Viral Nonstructural Proteins | 6 | 2018 | 228 | 0.460 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2014 | 113 | 0.450 |
Why?
|
Drug Therapy, Combination | 16 | 2019 | 6309 | 0.430 |
Why?
|
Macrocyclic Compounds | 3 | 2018 | 68 | 0.420 |
Why?
|
Transaminases | 1 | 2013 | 199 | 0.410 |
Why?
|
Preoperative Care | 3 | 2017 | 2249 | 0.410 |
Why?
|
Sulfonamides | 6 | 2020 | 1980 | 0.400 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15882 | 0.390 |
Why?
|
Middle Aged | 91 | 2024 | 223083 | 0.380 |
Why?
|
Humans | 153 | 2024 | 766117 | 0.370 |
Why?
|
Lypressin | 4 | 2023 | 26 | 0.370 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2012 | 293 | 0.370 |
Why?
|
Fatty Liver | 4 | 2024 | 810 | 0.340 |
Why?
|
Immunosuppressive Agents | 3 | 2017 | 4213 | 0.320 |
Why?
|
Varicose Veins | 2 | 2023 | 158 | 0.310 |
Why?
|
Organ Transplantation | 2 | 2017 | 1172 | 0.310 |
Why?
|
Male | 91 | 2024 | 363935 | 0.310 |
Why?
|
Treatment Outcome | 33 | 2024 | 65219 | 0.300 |
Why?
|
International Normalized Ratio | 2 | 2024 | 382 | 0.300 |
Why?
|
Spouses | 1 | 2011 | 286 | 0.300 |
Why?
|
RNA, Viral | 10 | 2018 | 2868 | 0.300 |
Why?
|
Retrospective Studies | 40 | 2024 | 81565 | 0.300 |
Why?
|
Quality of Life | 6 | 2011 | 13468 | 0.290 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 116 | 0.290 |
Why?
|
Fatigue | 3 | 2020 | 1552 | 0.290 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5531 | 0.280 |
Why?
|
Female | 91 | 2024 | 396233 | 0.280 |
Why?
|
Kidney Transplantation | 7 | 2022 | 4277 | 0.270 |
Why?
|
Diagnostic Techniques, Digestive System | 1 | 2007 | 45 | 0.270 |
Why?
|
Drug Administration Schedule | 8 | 2017 | 4853 | 0.270 |
Why?
|
Florida | 3 | 2013 | 416 | 0.270 |
Why?
|
Social Support | 2 | 2013 | 2190 | 0.260 |
Why?
|
Sirolimus | 2 | 2012 | 1541 | 0.260 |
Why?
|
Microspheres | 3 | 2024 | 773 | 0.250 |
Why?
|
Medication Adherence | 2 | 2017 | 2190 | 0.250 |
Why?
|
Adaptation, Psychological | 2 | 2013 | 2662 | 0.250 |
Why?
|
Multivariate Analysis | 8 | 2017 | 12061 | 0.240 |
Why?
|
Drug Resistance, Viral | 4 | 2017 | 868 | 0.230 |
Why?
|
Biliary Tract Diseases | 1 | 2005 | 160 | 0.230 |
Why?
|
Gallbladder Diseases | 1 | 2005 | 139 | 0.220 |
Why?
|
Hepatic Artery | 3 | 2018 | 233 | 0.210 |
Why?
|
Venous Thrombosis | 2 | 2023 | 1321 | 0.210 |
Why?
|
Aged | 44 | 2024 | 171219 | 0.210 |
Why?
|
Primary Graft Dysfunction | 3 | 2013 | 112 | 0.210 |
Why?
|
Adult | 59 | 2024 | 223139 | 0.210 |
Why?
|
Ceftriaxone | 1 | 2024 | 176 | 0.210 |
Why?
|
Recurrence | 8 | 2017 | 8494 | 0.200 |
Why?
|
Drug Combinations | 6 | 2020 | 2076 | 0.200 |
Why?
|
Hepatitis B, Chronic | 2 | 2022 | 413 | 0.200 |
Why?
|
Health Status | 2 | 2013 | 4086 | 0.200 |
Why?
|
Diffusion of Innovation | 1 | 2007 | 723 | 0.190 |
Why?
|
B-Lymphocyte Subsets | 1 | 2003 | 240 | 0.190 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2022 | 128 | 0.190 |
Why?
|
Ascites | 3 | 2023 | 336 | 0.190 |
Why?
|
Interferon Type I | 1 | 2005 | 568 | 0.190 |
Why?
|
Pyrrolidines | 2 | 2020 | 337 | 0.180 |
Why?
|
Sodium | 2 | 2024 | 1591 | 0.180 |
Why?
|
Logistic Models | 6 | 2021 | 13273 | 0.180 |
Why?
|
Cavernous Sinus | 1 | 2001 | 121 | 0.180 |
Why?
|
Creatinine | 2 | 2024 | 1916 | 0.180 |
Why?
|
Hepatic Encephalopathy | 2 | 2018 | 143 | 0.170 |
Why?
|
Hepatitis B Antibodies | 1 | 2000 | 156 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2016 | 1470 | 0.170 |
Why?
|
Pilot Projects | 5 | 2024 | 8724 | 0.170 |
Why?
|
Recovery of Function | 2 | 2012 | 2971 | 0.170 |
Why?
|
Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 167 | 0.170 |
Why?
|
Organ Preservation Solutions | 1 | 2000 | 105 | 0.170 |
Why?
|
Time Factors | 12 | 2017 | 40108 | 0.170 |
Why?
|
Graft Rejection | 4 | 2017 | 4504 | 0.170 |
Why?
|
Prognosis | 14 | 2023 | 29912 | 0.160 |
Why?
|
Kidney | 3 | 2022 | 7072 | 0.160 |
Why?
|
Mental Health | 1 | 2013 | 3273 | 0.160 |
Why?
|
North America | 1 | 2023 | 1287 | 0.160 |
Why?
|
Alanine Transaminase | 2 | 2015 | 608 | 0.160 |
Why?
|
Viremia | 2 | 2023 | 727 | 0.150 |
Why?
|
Interferon-alpha | 2 | 2014 | 909 | 0.150 |
Why?
|
United States | 18 | 2024 | 72920 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4887 | 0.150 |
Why?
|
Caregivers | 1 | 2011 | 2304 | 0.150 |
Why?
|
Viral Load | 5 | 2017 | 3386 | 0.150 |
Why?
|
Aminoisobutyric Acids | 4 | 2020 | 39 | 0.150 |
Why?
|
Respiratory Insufficiency | 3 | 2022 | 1241 | 0.150 |
Why?
|
Hypertension, Portal | 2 | 2017 | 229 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2001 | 514 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 527 | 0.140 |
Why?
|
Benzofurans | 1 | 2018 | 139 | 0.140 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 1189 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 1 | 2011 | 3230 | 0.140 |
Why?
|
Portal Pressure | 1 | 2017 | 62 | 0.140 |
Why?
|
New Zealand | 2 | 2014 | 360 | 0.140 |
Why?
|
Risk Assessment | 7 | 2021 | 24276 | 0.140 |
Why?
|
Hepatic Veins | 1 | 2017 | 112 | 0.140 |
Why?
|
Endoscopy, Digestive System | 1 | 2019 | 358 | 0.130 |
Why?
|
Balloon Occlusion | 1 | 2017 | 129 | 0.130 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 577 | 0.130 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 837 | 0.130 |
Why?
|
Cyclopropanes | 4 | 2020 | 436 | 0.130 |
Why?
|
Leucine | 4 | 2020 | 547 | 0.130 |
Why?
|
Hepatitis C Antibodies | 1 | 2016 | 151 | 0.130 |
Why?
|
Proline | 4 | 2020 | 453 | 0.130 |
Why?
|
Lactams, Macrocyclic | 4 | 2020 | 318 | 0.130 |
Why?
|
Interferons | 2 | 2017 | 714 | 0.130 |
Why?
|
Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2023 | 1318 | 0.130 |
Why?
|
Hepatitis, Chronic | 2 | 2011 | 53 | 0.130 |
Why?
|
Lamivudine | 2 | 2010 | 368 | 0.130 |
Why?
|
Cystic Fibrosis | 1 | 2005 | 1284 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 624 | 0.130 |
Why?
|
Antigens, CD | 2 | 2003 | 4025 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2024 | 5300 | 0.120 |
Why?
|
Ultrasonography, Interventional | 1 | 2024 | 1520 | 0.120 |
Why?
|
Predictive Value of Tests | 9 | 2024 | 15403 | 0.120 |
Why?
|
Albumins | 3 | 2023 | 578 | 0.120 |
Why?
|
Mood Disorders | 2 | 2013 | 1127 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2011 | 4527 | 0.120 |
Why?
|
Neurotransmitter Agents | 1 | 2019 | 661 | 0.120 |
Why?
|
Cohort Studies | 16 | 2021 | 41684 | 0.120 |
Why?
|
Graft Occlusion, Vascular | 1 | 2018 | 539 | 0.120 |
Why?
|
Ammonia | 1 | 2016 | 244 | 0.120 |
Why?
|
Death | 2 | 2011 | 686 | 0.120 |
Why?
|
Cell Separation | 1 | 2000 | 1718 | 0.120 |
Why?
|
Cytokines | 3 | 2019 | 7426 | 0.120 |
Why?
|
Patient Selection | 4 | 2018 | 4249 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 1 | 2017 | 179 | 0.120 |
Why?
|
Blood Chemical Analysis | 2 | 2015 | 434 | 0.120 |
Why?
|
Nephrectomy | 1 | 2020 | 928 | 0.120 |
Why?
|
Graft Survival | 6 | 2018 | 3904 | 0.120 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 591 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2016 | 327 | 0.120 |
Why?
|
Portal Vein | 3 | 2023 | 437 | 0.110 |
Why?
|
Bronchial Neoplasms | 1 | 2014 | 109 | 0.110 |
Why?
|
Transplants | 1 | 2016 | 208 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2015 | 238 | 0.110 |
Why?
|
HIV Infections | 6 | 2017 | 17535 | 0.110 |
Why?
|
Lipase | 1 | 2016 | 320 | 0.110 |
Why?
|
Risk Factors | 16 | 2022 | 74857 | 0.110 |
Why?
|
Aspartate Aminotransferases | 1 | 2014 | 416 | 0.100 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 697 | 0.100 |
Why?
|
Membrane Proteins | 2 | 2016 | 7850 | 0.100 |
Why?
|
Postoperative Complications | 6 | 2017 | 15808 | 0.100 |
Why?
|
Glomerulonephritis, IGA | 1 | 2013 | 61 | 0.100 |
Why?
|
Lymphocytes | 1 | 2000 | 2602 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 676 | 0.100 |
Why?
|
BK Virus | 1 | 2013 | 120 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1169 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2011 | 2419 | 0.100 |
Why?
|
Thrombosis | 3 | 2022 | 2955 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2024 | 3853 | 0.100 |
Why?
|
Biopsy | 6 | 2017 | 6768 | 0.090 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 584 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 551 | 0.090 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3432 | 0.090 |
Why?
|
Fibrosis | 3 | 2024 | 2073 | 0.090 |
Why?
|
Hepatitis B virus | 2 | 2012 | 532 | 0.090 |
Why?
|
Interleukins | 1 | 2016 | 789 | 0.090 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7843 | 0.090 |
Why?
|
Polyomavirus Infections | 1 | 2013 | 193 | 0.090 |
Why?
|
Cold Ischemia | 1 | 2011 | 72 | 0.090 |
Why?
|
Prevalence | 3 | 2021 | 15827 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1405 | 0.090 |
Why?
|
Aged, 80 and over | 9 | 2020 | 59515 | 0.090 |
Why?
|
Health Personnel | 2 | 2023 | 3387 | 0.090 |
Why?
|
Tumor Virus Infections | 1 | 2013 | 438 | 0.090 |
Why?
|
Platelet Count | 1 | 2013 | 784 | 0.090 |
Why?
|
Disease Management | 2 | 2020 | 2531 | 0.080 |
Why?
|
Renal Replacement Therapy | 2 | 2023 | 282 | 0.080 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4282 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6506 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2013 | 1588 | 0.080 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4860 | 0.080 |
Why?
|
Young Adult | 11 | 2022 | 59868 | 0.080 |
Why?
|
Abdomen | 1 | 2015 | 1135 | 0.080 |
Why?
|
Keratin-18 | 1 | 2009 | 37 | 0.080 |
Why?
|
Polytetrafluoroethylene | 1 | 2010 | 242 | 0.080 |
Why?
|
Pulmonary Veins | 1 | 2015 | 759 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3930 | 0.080 |
Why?
|
Affective Symptoms | 1 | 2011 | 418 | 0.080 |
Why?
|
Postoperative Period | 1 | 2013 | 1820 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
Attitude to Death | 1 | 2011 | 400 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12235 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2926 | 0.070 |
Why?
|
Thrombectomy | 2 | 2023 | 676 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2016 | 9237 | 0.070 |
Why?
|
Europe | 1 | 2014 | 3430 | 0.070 |
Why?
|
Primary Health Care | 2 | 2021 | 4736 | 0.070 |
Why?
|
Ventilator Weaning | 1 | 2008 | 170 | 0.070 |
Why?
|
Linear Models | 2 | 2021 | 5873 | 0.070 |
Why?
|
Th1 Cells | 2 | 2002 | 1041 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1729 | 0.070 |
Why?
|
Sensitivity and Specificity | 5 | 2015 | 14645 | 0.070 |
Why?
|
Cyclosporine | 1 | 2009 | 777 | 0.070 |
Why?
|
Methylene Blue | 1 | 2007 | 156 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 949 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1075 | 0.070 |
Why?
|
Personal Satisfaction | 1 | 2011 | 641 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2000 | 4782 | 0.070 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1938 | 0.060 |
Why?
|
Tissue and Organ Procurement | 3 | 2012 | 988 | 0.060 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39243 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5454 | 0.060 |
Why?
|
Survival Rate | 6 | 2021 | 12827 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2001 | 4049 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3530 | 0.060 |
Why?
|
Immunoglobulins | 2 | 2010 | 853 | 0.060 |
Why?
|
Liver Function Tests | 2 | 2005 | 527 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2023 | 3477 | 0.060 |
Why?
|
Tacrolimus | 1 | 2009 | 754 | 0.060 |
Why?
|
Fatal Outcome | 3 | 2014 | 1836 | 0.060 |
Why?
|
Intubation | 1 | 2005 | 140 | 0.060 |
Why?
|
SEER Program | 2 | 2021 | 1443 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8038 | 0.060 |
Why?
|
Viral Envelope Proteins | 2 | 2013 | 639 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5752 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10380 | 0.060 |
Why?
|
Information Storage and Retrieval | 2 | 2021 | 831 | 0.060 |
Why?
|
Coronary Artery Disease | 2 | 2021 | 6544 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3186 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6493 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1941 | 0.060 |
Why?
|
Biliary Tract | 1 | 2005 | 137 | 0.060 |
Why?
|
Survival Analysis | 4 | 2020 | 10087 | 0.060 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2002 | 317 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 20700 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5695 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2007 | 911 | 0.060 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 132 | 0.060 |
Why?
|
Genes, MHC Class I | 1 | 2004 | 236 | 0.050 |
Why?
|
Boston | 3 | 2012 | 9335 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20137 | 0.050 |
Why?
|
Gallbladder | 1 | 2005 | 308 | 0.050 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 2474 | 0.050 |
Why?
|
Genes, MHC Class II | 1 | 2004 | 433 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2002 | 2206 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4904 | 0.050 |
Why?
|
Ontario | 1 | 2024 | 403 | 0.050 |
Why?
|
Adolescent | 8 | 2021 | 88819 | 0.050 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2022 | 84 | 0.050 |
Why?
|
Attitude to Health | 1 | 2011 | 2020 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 168 | 0.050 |
Why?
|
Terminal Care | 1 | 2014 | 1769 | 0.050 |
Why?
|
Reoperation | 3 | 2018 | 4309 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5889 | 0.050 |
Why?
|
Tissue and Organ Harvesting | 1 | 2005 | 373 | 0.050 |
Why?
|
K562 Cells | 2 | 2002 | 644 | 0.050 |
Why?
|
Endoscopy | 3 | 2017 | 1854 | 0.050 |
Why?
|
Hypotension | 1 | 2008 | 885 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 439 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 452 | 0.050 |
Why?
|
Complement Pathway, Classical | 1 | 2001 | 82 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 7050 | 0.050 |
Why?
|
Immunophenotyping | 3 | 2002 | 1865 | 0.050 |
Why?
|
Viral Core Proteins | 1 | 2002 | 158 | 0.050 |
Why?
|
Suction | 1 | 2022 | 268 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9657 | 0.050 |
Why?
|
Diffusion Tensor Imaging | 1 | 2012 | 2415 | 0.050 |
Why?
|
Pentanoic Acids | 1 | 2020 | 19 | 0.050 |
Why?
|
Complement C4 | 1 | 2001 | 208 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26290 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4044 | 0.040 |
Why?
|
Raffinose | 1 | 2000 | 57 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2021 | 2227 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8882 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1613 | 0.040 |
Why?
|
Device Removal | 1 | 2005 | 643 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2004 | 4408 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 2232 | 0.040 |
Why?
|
Blood Component Transfusion | 1 | 2021 | 141 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2021 | 12426 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5988 | 0.040 |
Why?
|
Donor Selection | 1 | 2022 | 242 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2021 | 385 | 0.040 |
Why?
|
Neutropenia | 1 | 2005 | 894 | 0.040 |
Why?
|
Prospective Studies | 6 | 2024 | 54812 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 307 | 0.040 |
Why?
|
Morbidity | 1 | 2005 | 1753 | 0.040 |
Why?
|
Palliative Care | 1 | 2014 | 3639 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 445 | 0.040 |
Why?
|
Alanine | 1 | 2022 | 613 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 702 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2002 | 592 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 622 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 36548 | 0.040 |
Why?
|
Rheumatoid Factor | 1 | 2000 | 183 | 0.040 |
Why?
|
Medicare | 3 | 2023 | 6820 | 0.040 |
Why?
|
Allopurinol | 1 | 2000 | 203 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4649 | 0.040 |
Why?
|
Living Donors | 1 | 2023 | 647 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2023 | 753 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2000 | 444 | 0.040 |
Why?
|
Constriction, Pathologic | 2 | 2018 | 1102 | 0.040 |
Why?
|
Acute Disease | 2 | 2017 | 7237 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3238 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1614 | 0.040 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 827 | 0.040 |
Why?
|
Angiography | 1 | 2023 | 1589 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13635 | 0.040 |
Why?
|
Plasma | 1 | 2021 | 583 | 0.040 |
Why?
|
Glutathione | 1 | 2000 | 589 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6059 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 11837 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2014 | 3798 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2005 | 1172 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8525 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2018 | 331 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4418 | 0.030 |
Why?
|
Osteolysis | 1 | 1999 | 271 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1999 | 361 | 0.030 |
Why?
|
Lipoproteins | 1 | 2021 | 870 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2021 | 488 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2012 | 22228 | 0.030 |
Why?
|
Mesenteric Veins | 1 | 1997 | 87 | 0.030 |
Why?
|
Endopeptidases | 1 | 2000 | 760 | 0.030 |
Why?
|
Antigens, CD19 | 1 | 2000 | 442 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16716 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 4112 | 0.030 |
Why?
|
Israel | 1 | 2019 | 729 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2000 | 1149 | 0.030 |
Why?
|
Pain | 1 | 2011 | 5090 | 0.030 |
Why?
|
Pruritus | 1 | 2020 | 376 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 1416 | 0.030 |
Why?
|
HLA-DR Antigens | 3 | 2004 | 608 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16040 | 0.030 |
Why?
|
Serine Proteases | 1 | 2016 | 44 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2023 | 2426 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2002 | 1362 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6206 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2002 | 5881 | 0.030 |
Why?
|
Antibody Formation | 1 | 2000 | 1392 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2000 | 1441 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1514 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 1218 | 0.030 |
Why?
|
Alleles | 2 | 2004 | 6892 | 0.030 |
Why?
|
Adenosine | 1 | 2000 | 813 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2205 | 0.030 |
Why?
|
Body Mass Index | 2 | 2010 | 13046 | 0.030 |
Why?
|
Interferon-gamma | 2 | 2002 | 3159 | 0.030 |
Why?
|
Software | 2 | 2024 | 4463 | 0.030 |
Why?
|
Vascular Patency | 1 | 2018 | 914 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 418 | 0.030 |
Why?
|
Patient Compliance | 1 | 2005 | 2694 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11200 | 0.030 |
Why?
|
HIV | 2 | 2014 | 1587 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2002 | 1996 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2002 | 1814 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
Ischemia | 1 | 2023 | 1904 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1735 | 0.030 |
Why?
|
Cholestasis | 1 | 2017 | 385 | 0.030 |
Why?
|
Gastroenterology | 1 | 2000 | 593 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15647 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 820 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2002 | 2570 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2017 | 750 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2017 | 5340 | 0.030 |
Why?
|
Spain | 1 | 2014 | 483 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 716 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1945 | 0.030 |
Why?
|
Advance Directives | 1 | 2014 | 249 | 0.030 |
Why?
|
Heart Diseases | 1 | 2005 | 2818 | 0.030 |
Why?
|
Cholesterol | 1 | 2021 | 2902 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 878 | 0.020 |
Why?
|
Vaccination | 1 | 2004 | 3431 | 0.020 |
Why?
|
Disease Progression | 3 | 2016 | 13616 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2017 | 11035 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2011 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2653 | 0.020 |
Why?
|
Headache | 1 | 2020 | 1259 | 0.020 |
Why?
|
Hemorrhage | 1 | 2024 | 3466 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 22344 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2915 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6208 | 0.020 |
Why?
|
Oligopeptides | 1 | 2016 | 1195 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2195 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2013 | 225 | 0.020 |
Why?
|
Child | 4 | 2023 | 80573 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3214 | 0.020 |
Why?
|
Cell Survival | 1 | 2000 | 5747 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1740 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 1478 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2936 | 0.020 |
Why?
|
Bone Marrow | 1 | 2000 | 2916 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2021 | 4498 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2897 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9354 | 0.020 |
Why?
|
Databases, Factual | 2 | 2020 | 8062 | 0.020 |
Why?
|
Echocardiography | 1 | 2022 | 5041 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7424 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 150 | 0.020 |
Why?
|
Anisotropy | 1 | 2012 | 1284 | 0.020 |
Why?
|
Bronchoscopy | 1 | 2014 | 913 | 0.020 |
Why?
|
Computer Simulation | 2 | 2012 | 6254 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4016 | 0.020 |
Why?
|
Hepatitis | 1 | 2010 | 226 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5595 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2260 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3405 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1629 | 0.020 |
Why?
|
Interleukin-10 | 2 | 2004 | 1181 | 0.020 |
Why?
|
Colonoscopy | 1 | 2015 | 1408 | 0.020 |
Why?
|
Age Factors | 3 | 2009 | 18386 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 135 | 0.020 |
Why?
|
Genetic Variation | 1 | 2002 | 6612 | 0.020 |
Why?
|
DNA, Viral | 1 | 2014 | 2200 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12775 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2006 | 0.020 |
Why?
|
Lectins | 1 | 2009 | 487 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4133 | 0.020 |
Why?
|
Adipokines | 1 | 2009 | 308 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1238 | 0.020 |
Why?
|
Stents | 1 | 2018 | 3191 | 0.020 |
Why?
|
Renal Circulation | 1 | 2007 | 288 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2844 | 0.020 |
Why?
|
Viruses | 1 | 2010 | 371 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2010 | 547 | 0.020 |
Why?
|
Radiography | 2 | 2009 | 6943 | 0.020 |
Why?
|
Insulin | 1 | 2000 | 6604 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6840 | 0.020 |
Why?
|
Hyaluronic Acid | 1 | 2009 | 483 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12976 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3955 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 1997 | 2249 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10737 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2000 | 18967 | 0.010 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.010 |
Why?
|
Pancreas Transplantation | 1 | 2005 | 194 | 0.010 |
Why?
|
JC Virus | 1 | 2005 | 87 | 0.010 |
Why?
|
Rho(D) Immune Globulin | 1 | 2004 | 34 | 0.010 |
Why?
|
Resource Allocation | 1 | 2007 | 354 | 0.010 |
Why?
|
Cardiac Output | 1 | 2007 | 838 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 2011 | 1043 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10579 | 0.010 |
Why?
|
Virus Diseases | 1 | 2010 | 720 | 0.010 |
Why?
|
HLA-A Antigens | 1 | 2004 | 223 | 0.010 |
Why?
|
Algorithms | 1 | 2024 | 14066 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2306 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2504 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5330 | 0.010 |
Why?
|
Registries | 1 | 2020 | 8347 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3715 | 0.010 |
Why?
|
Receptors, KIR2DL1 | 1 | 2002 | 13 | 0.010 |
Why?
|
Receptors, KIR2DL3 | 1 | 2002 | 15 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2002 | 30 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2002 | 42 | 0.010 |
Why?
|
Mast-Cell Sarcoma | 1 | 2002 | 46 | 0.010 |
Why?
|
Receptors, KIR3DL1 | 1 | 2002 | 27 | 0.010 |
Why?
|
Drug Contamination | 1 | 2004 | 151 | 0.010 |
Why?
|
Mental Disorders | 2 | 2017 | 6871 | 0.010 |
Why?
|
Brain | 2 | 2012 | 27177 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8725 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3690 | 0.010 |
Why?
|
Receptors, KIR | 1 | 2002 | 114 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2702 | 0.010 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2001 | 91 | 0.010 |
Why?
|
Blood Pressure | 2 | 2008 | 8532 | 0.010 |
Why?
|
Electroencephalography | 1 | 2017 | 6279 | 0.010 |
Why?
|
Glycoproteins | 1 | 2009 | 2196 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12529 | 0.010 |
Why?
|
Interleukin-5 | 1 | 2002 | 268 | 0.010 |
Why?
|
Critical Illness | 1 | 2014 | 2749 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 2002 | 225 | 0.010 |
Why?
|
Edetic Acid | 1 | 2001 | 274 | 0.010 |
Why?
|
ROC Curve | 1 | 2009 | 3614 | 0.010 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1359 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 453 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2000 | 190 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2005 | 865 | 0.010 |
Why?
|
Incidence | 2 | 2008 | 21513 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 1346 | 0.010 |
Why?
|
Cell Count | 1 | 2002 | 1825 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 812 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2000 | 726 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 2000 | 463 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 1607 | 0.010 |
Why?
|
Cold Temperature | 1 | 2001 | 794 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2689 | 0.010 |
Why?
|
Mice | 2 | 2002 | 81839 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6545 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6102 | 0.010 |
Why?
|
Phylogeny | 1 | 2002 | 2838 | 0.010 |
Why?
|
Monocytes | 1 | 2004 | 2591 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2002 | 1889 | 0.010 |
Why?
|
Haplotypes | 1 | 2000 | 2726 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14747 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 1997 | 992 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4909 | 0.010 |
Why?
|
Animals | 2 | 2002 | 168800 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 13400 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17597 | 0.010 |
Why?
|
Child, Preschool | 1 | 2012 | 42511 | 0.000 |
Why?
|
Bone and Bones | 1 | 1999 | 2555 | 0.000 |
Why?
|
Inflammation | 1 | 2007 | 10860 | 0.000 |
Why?
|
Bone Density | 1 | 1999 | 3491 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 2002 | 6363 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2002 | 6961 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2000 | 11642 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2000 | 18076 | 0.000 |
Why?
|